Why SHAMBAUGH
SHAMBAUGH has more than twenty years of research and success in applying integrated solutions to address today's business leadership challenges.
We're unique thanks to our
- Customized approach
- Proven process
- Peer-to-peer framework
- Long-term solutions
WILL Alumni Advisory Board
Christine Dingivan, M.D., joined PPD in 2008 to serve as executive vice president and chief medical officer. As the company’s chief medical officer, she holds primary responsibility for medical assessment of clinical research and adherence to ethical standards and good laboratory practices. She also provides leadership and strategic direction to global regulatory affairs and pharmacovigilance, biomarker discovery sciences, the company’s Phase I clinic, and bioanalytical and cGMP laboratory services.
Dr. Dingivan came to PPD from MedImmune, a worldwide biologics business acquired by AstraZeneca PLC in 2007, where she most recently served as senior vice president of clinical development and operations. While at MedImmune, she also oversaw strategic development and implementation of global clinical research programs across all therapeutic areas, provided senior clinical leadership for U.S. and European regulatory applications, and chaired the clinical safety monitoring committee.
Dr. Dingivan received her undergraduate degree in bioengineering from the University of Pennsylvania and medical degree from Dartmouth Medical School. She trained in general surgery at Northwestern University Medical School’s department of surgery.